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Introduction
Genomic instability and acquired genetic mutations have been well-documented as relevant drivers of the multi-step oncogenic process. 1 While much progress has been made in understanding the complex interplay between genetic, inflammatory, and microenvironmental variables in cancer etiology, the contribution of aberrant epigenetic regulation in driving initiation and maintenance of malignancy remains incompletely characterized. A major limiting factor in documenting the progression of aberrant epigenetic activity that occurs during cellular immortalization and transformation has been the lack of spontaneous, reproducible models.
The Epstein-Barr virus (EBV) is a human, B-lymphotropic, γ-herpesvirus associated with the development of B-cell lymphomas. 2 Here we address the significance of the dysregulation of an epigenetic modifier, the protein arginine methyltransferases-5 (PRMT5), during the transformation process using EBV as a tool to drive B lymphocyte immortalization and maintenance of the malignant phenotype.
The human genome encodes eleven protein arginine methyltransferases (PRMTs) that covalently modify arginine residues in histone and non-histone proteins contributing to a wide variety of cellular regulatory networks. [3] [4] [5] [6] Both type I and II PRMTs catalyze monomethylation at the ω -NH2 of arginine however they differ in their ability to add the second methyl group, either asymmetrically (Type I) or symmetrically (Type II). 3, 4, 6 PRMT5 is a type II arginine methyltransferase that catalyzes symmetric dimethylation of histone proteins H3 (S2Me-H3R8) and H4 (S2Me-H4R3) altering chromatin structure to promote transcriptional target gene silencing. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] A growing number of non-histone proteins involved in the control of multiple regulatory networks including the EBV-encoded gene products EBNA1 and EBNA2 have also been identified to interact with PRMT5. 4, [17] [18] [19] [20] [21] PRMT5 overexpression is involved in the proliferation and survival of mantle cell (MCL) 15 and diffuse large B cell lymphoma (DLBCL) cells. 22 While these studies demonstrated direct association between PRMT5 and malignant B-cell survival and proliferation, the overall relevance of PRMT5 overexpression during the transformation process remains unclear.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Here, we demonstrate PRMT5 overexpression to be dependent on a LMP-1-driven NF-kBrepressive complex recruited to the miR96 promoter which silences this regulatory miR and promotes PRMT5 overexpression, its translocation to the B lymphoblast nucleus and transcriptional silencing of critical tumor suppressor genes. We target this oncogenic pathway with a first-in-class, highly selective, small molecule inhibitor of PRMT5 that allowed us to study the epigenetic events occurring during B-cell transformation. Interfering with PRMT5 activity prevents establishment of B-cell immortalization and maintenance of malignant phenotype, in part, by affecting differential NF-kB/p65 subunit association with transcriptional activation complexes that restore expression of tumor suppressors. This work provides insight into the essential contribution of PRMT5 to B-cell lymphomagenesis, and provides rationale for targeting this enzyme in B-cell Non-Hodgkin's lymphomas (NHLs). 
Methods

In vivo development of spontaneous EBV-lymphomas
Results
PRMT5 is overexpressed in EBV+ primary lymphomas, EBV-transformed andimmortalized B cells
IHC of 23 primary human EBV+ lymphomas showed that both PRMT5 and associated epigenetic marks, S2Me-H4R3 and S2Me-H3R8, were markedly overexpressed with a nuclear/cytoplasmic pattern in all cases of EBV + lymphomas and EBV-LPD as compared to normal or reactive lymph nodes (Table 1 and Figure 1A ).
Primary tumors from the hu-PBL-SCID mouse model of EBV-lymphoma (n=3) also assessed by IHC showed abundant levels of cytoplasmic and nuclear PRMT5 (Supplemental Figure 1 ).
Western blot analysis of transformed LCLs (60A, C7M3, 100, 147) confirmed PRMT5 overexpression whereas resting or activated B lymphocyte, CD4+ T cell, CD8+ T cell and monocyte preparations did not, suggesting that PRMT5 expression is associated with a malignant phenotype rather than proliferation of physiologically activated B lymphocytes ( Figure 1B Figure 1D ).
Confocal microscopy studies documented detection of PRMT5 as early as 4 days post infection ( Figure 1E ), a time that coincided with expression of the LMP1 viral oncoprotein ( Figure 1F ), translocation of PRMT5 from cytoplasm to nucleus as early as day 8 post infection and continued increase of nuclear expression intensity during the immortalization process, eventually becoming equivalent to that seen in transformed LCLs ( Figure 1E ). Expression of high levels of nuclear PRMT5 coincided with acquisition of global PRMT5-catalyzed histone epigenetic marks (S2Me-H4R3 and S2Me-H3R8) ( Figure 1G ) with relative loss of the type I PRMT1 asymmetric histone mark A2Me2-H4R3 (Supplemental Figure 3 ). These observations led us to hypothesize that PRMT5 overexpression occurred soon after EBV infection rather than being acquired after establishment of the transformed state.
PRMT5 is a therapeutic target for B-cell NHLs.
Pilot experiments evaluating the effects of shRNA knockdown of PRMT5 in LCLs led to decreased viability (Supplemental Figure 4A and data not shown). EBV-immortalization assays with B lymphocytes transfected with lentiviral preparations designed to express a PRMT5 cDNA showed enhanced viability and proliferation 5 and 12 days following infection while cells transfected with a shRNA designed to knockdown PRMT5 showed reduced viability (Supplemental Figure 4B and 4C) (p<0.05). These observations supported the notion that PRMT5 overexpression may serve as an important mechanism promoting B cell immortalization after EBV infection.
Development of a first-in-class small molecule PRMT5 inhibitor.
The initial lack of a crystal structure of human PRMT5 (hPRMT5) led us to utilize a comparative modeling and structure-based virtual screening approach to identify compounds that could specifically inhibit PRMT5 activity.
Multiple crystal structures of homologous arginine methyltransferases were used in the For personal use only. on October 24, 2017. by guest www.bloodjournal.org From hPRMT5 model building process. The crystal structure of rat PRMT1 (rPRMT1) showed highest homology to hPRMT5 and provided the primary template for modeling. Overlay of the in silico model of the hPRMT5 catalytic domain with the rPRMT1 crystal structure 25, 26 showed a nearly identical alignment ( Figure 2A ) with a backbone α -carbon root mean squared deviation (RMSD) of 1.14 Å, supporting the conserved nature of the catalytic domains of this enzyme family (Figure 2A -C). Further, we were able to computationally dock SAH and substrate arginine residue successfully to the respective binding pockets within the hPRMT5 model, thus validating the catalytic site for the purpose of structure-based drug design ( Figure   2C and D).
Using a structure-based computational and combinatorial lead optimization method, we utilized our hPRMT5 catalytic site model to screen the ChemBridge CNS-Set™ library of 10,000 small molecule compounds (CMPs). Virtual docking of candidate small molecules revealed a select number of structures to associate with low binding energy in S-adenosyl-L-methionine (SAM) cofactor and arginine binding pockets (identified as red and blue regions in Figure 2A , respectively). Initial testing identified 8 CMPs with lowest binding energy (Supplemental Figure   5A and 5B) for screening assays using immunofluorescence for ability to inhibit type I or type II H4R3 methylation in JeKo cells ( Figure 2F ). Cellular screening assays allowed us to identify CMP5 ( Figure 2G and Supplemental Figure 5 ) as the optimal candidate inhibitor for further study. Unlike other CMPs including CMP6 ( Figure 2G ), with no effect on H4R3 methylation, CMP5 was found to selectively block S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity ( Figure 2H ) on histone preparations. Moreover, CMP5 was inactive against other type I (PRMT1 and PRMT4) and type II (PRMT7) enzymes, underscoring its specificity toward PRMT5 ( Figure 2H ).
The initial predicted binding interactions of CMP5 with the hPRMT5 model suggested that the pyridine ring of CMP5 could form π -stacking interaction with Phe327 residue (Figure 2E ), which was hypothesized to be critical for directing the ability of PRMT5 to catalyze symmetric dimethylation of arginine, 27 also potentially explaining the selectivity of CMP5 for type-II PRMT5 not type-I PRMTs. When our in silico model was compared to the recently reported crystal structure of hPRMT5 ( Figure 2I , purple ribbon), 28 we found our catalytic domain model to be nearly identical ( Figure 2I , green ribbon). Additionally, alignment of the amino acid residues within 6 Å of the catalytic site residues of our model produced a lower RMSD of 1.17 Å, demonstrating a better agreement with the catalytic site residues ( Figure 2J ). A few differences were also observed from the crystal structure, notably the rotamer placement of Glu444. The orientation of this Glu444 is toward the solvent accessible surface in the model while the crystal structure orientation is rotated at a dihedral angle of 102°. Due to these differences, CMP5 docked to the hPRMT5 crystal structure showed that the carbazole ring occupied a space toward the cofactor adenosine binding position ( Figure 2K ) instead of the cofactor methionine subpocket initially predicted with the homology model ( Figure 2E ).
Cytotoxicity studies showed that treatment with increasing concentrations of CMP5 was selectively toxic to lymphoma cells ( Figure 2L , 2N and 2O) (p<0.05), while demonstrating limited toxicity to normal resting B lymphocytes even after prolonged incubation (48 and 72 hours, Figure 2M ). In addition, while CMP5 treatment of LCLs led to loss of PRMT5 epigenetic marks, S2Me-H4R3 and S2Me-H3R8, it did not affect asymmetric methylation of H4R3, a type I PRMT histone mark (Supplemental Figure 6 ). Collectively, these data demonstrate that PRMT5 inhibition leads to selective tumor cell death and that PRMT5 is an ideal therapeutic target given its selective overexpression in malignant cells.
Selective PRMT5 inhibition prevents EBV-driven B cell immortalization and leads to global gene de-repression.
We performed EBV-B cell immortalization assays using a shRNA-lentiviral PRMT5 knockdown and CMP5-based approach. Normal B cells were infected with EBV: shRNA (or control scrambled shRNA) was added to cultures on day 8 ( Figure 3A and B), CMP5 (or DMSO vehicle control or non-reactive CMP6, Figure 3C ) was added on days 4, 7, 14, and 21.
Conditions were monitored every 3-5 days for proliferation/cell viability and absolute lymphocyte number. Knockdown with shRNA and selective inhibition of PRMT5 activity ( Figure   3B and C), prevented EBV infection from driving B cell survival, suggesting that PRMT5 is essential to support initiation of B-cell immortalization and maintenance of the transformed phenotype.
RNA-sequencing in transformed LCLs (60A) revealed significant de-repression of the genome with CMP5 treatment (402 upregulated genes at 12 hours vs 149 downregulated genes) (p<0.005) and identified an enrichment for IRF4 and SREBP1/2 targets (p<0.005; Supplemental Figure 7 ). We also performed RNA-seq of PRMT5-shRNA treated 60A cells and observed significant overlap between genes de-repressed by CMP5 and genes de-repressed by PRMT5-shRNA (24 genes; p<0.005), confirming the specificity of our compound. While the functional significance of the PRMT5 de-repressed program remains to be elucidated, these results confirm the direct role of PRMT5 as a global transcriptional repressor.
Post transcriptional regulation of PRMT5 expression in EBV-transformed andimmortalized B cells.
In contrast to what we observed at the protein level, transformed LCLs showed markedly reduced levels of PRMT5 transcript compared to resting B cells (p<0.005) ( Figure 4A ). qRT-PCR on RNA harvested at various times following B cell infection with EBV showed decrease in PRMT5 transcript as early as day 8 ( Figure 4B ) (p<0.01), a time when protein expression was clearly observed ( Figure 1D and 1E) . We have previously reported on the post transcriptional nature of PRMT5-induced expression via repression of miR96 in MCL. 15 Similarly to what we previously observed, we found miR96 levels to be significantly lower in transformed LCLs when compared to resting B lymphocytes (p<0.005) ( Figure 4C ). We also documented a sharp decline in miR96 levels during B lymphocyte immortalization that appeared as early as day 4, became significant by day 8 post infection ( Figure 4D Figure 5D ) as well as S2Me2-H4R3 ( Figure 5E ), supporting the hypothesis that LMP1-driven NF-kB activity was contributing toward transcriptional repression of miR96. Use of the selective HDAC1,2 inhibitor JQ12 failed to significantly enhance miR96 expression ( Figure 5F ), while use of the broad spectrum HDAC inhibitor AR42 and the selective HDAC1,3 inhibitor MS275 led to statistically significant (p<0.05) enhanced miR96 expression ( Figure 5G and H, respectively), supporting the role of HDAC3 as a critical component of a transcriptional repressive complex. Treatment of LCLs with MS275 led to hyperacetylation of H3K14, a known HDAC3 target, confirming the specificity of this inhibitor ( Figure 5I ). 33 ChIP studies with antibodies specific for PRMT5, S2Me-H4R3 and S2Me-H3R8 showed significant enrichment of PRMT5 and its marks at the miR96 promoter in the LCL 60A ( Figure   6A ) (p<0.01). Additionally, knockdown (shRNA) or inhibition of PRMT5 with CMP5 led to loss of recruitment of PRMT5 and its epigenetic marks on the miR96 promoter ( Figure 6B and C) (p<0.05) and transcriptional de-repression of miR96 ( Figure 6D and E) (p<0.01). ChIP studies were also performed with antibodies against p65, HDAC3, and the epigenetic marks Ac-H4K8, Ac-H3K14, and Ac-H2BK12 in 60A cells treated either with PRMT5-shRNA or CMP5. PRMT5 knockdown and inhibition demonstrated enhanced recruitment of p65, loss of HDAC3 and hyperacetylation of lysine marks on histones H3, H4 and H2B, consistent with restored transcriptional activity of miR96 ( Figure 6F and G). 34, 35 In addition, IP experiments in an immortalized LCL (D-22) and in a transformed LCL (60A) showed physical association between PRMT5 and HDAC3 ( Figure 6H , top panel) and between HDAC3 and p65 (Figure 6 H, bottom panel). Treatment with CMP5 led to disruption of this repressive complex (HDAC3, PRMT5) and loss of recruitment at the miR96 promoter with simultaneous enhanced recruitment of p65 with the histone acetyltransferase p300, enhanced acetylation of histone marks and activation of miR96 transcription ( Figure 6I ). These studies document, for the first time, how, NF-kB repressive complexes driving lysine deacetylation, coordinate with PRMT5 to silence a critical miR that is vital to support its own expression in lymphoma cells. Figure 8E) . These observations support the notion that EBV utilizes PRMT5 to target and silence genes with important tumor suppressor properties during B cell immortalization, and that sustained PRMT5 activity is critical for supporting the malignant phenotype.
PRMT5 overexpression leads to recruitment and epigenetic repression of tumor suppressors ST7 and PTPROt
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Discussion
PRMT5 associates with chromatin remodeling complexes containing HDACs, MBD2 and
DNMT3a enzyme to silence the transcription of regulatory genes by catalyzing symmetric dimethylation of arginine residues on histone tails. 7, 8, 15, 16, 38 PRMT5 is overexpressed in a variety of lymphomas, including MCL and DLBCLs, and PRMT5 knockdown leads to apoptosis by restoration of the RBL2/E2F tumor suppressor pathway, transcriptional silencing of the PRC2 genes (EZH2, SUZ12, EED) and restored expression of proapoptotic EZH2-target genes (CASP10 and DAP1). 15, 16, 22 Furthermore, PRMT5 is necessary for CYCLIN-D1mediated neoplastic growth and proliferation through transcriptional repression of CUL4. 3 Finally, it has been recently shown that PRMT5 can activate NF-kB by physical association and dimethylation of the NF-Kb subunit p65 18 and that PRMT5 can mediate p53 methylation promoting G1 arrest in response to DNA damage. 4 In this study, we used in vitro and in vivo models of EBV immortalization and transformation to understand how post-translational changes of histones impact gene expression, the mechanism of PRMT5 dysregulation and how perturbation of these processes contributes to lymphomagenesis. It has been previously shown that early passages of immortalized LCLs have poor ability to grow in soft agar or to generate tumors in nude mice. 39 However it must be said that both immortalized LCLs and human EBV-LPD tumor cells from hu-PBL-SCID mice have been shown to induce LPD in SCID mice. 40 Although in vitro generated LCLs and fully transformed cell lines might represent different aspects of the same disease, in vitro generated LCLs express the same viral genes as EBV lymphomas, 41 therefore we believe that both systems represent a useful and reliable model for studying EBV mediated B cell oncogenesis.
We showed that PRMT5, while not expressed in normal or activated B cells, is markedly overexpressed in primary EBV+ lymphomas and LCLs, suggesting that PRMT5 overexpression is a marker of cellular transformation rather than proliferation. In addition to symmetric dimethylation of H4R3, PRMT5 also induces symmetric dimethylation of H3R8 with loss of asymmetric methylation of H4R3, a type I PRMT histone mark, indicating a global chromatin-wide repressive epigenetic change very early after EBV infection of B cells.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Development of a first-in-class small molecule inhibitor of PRMT5 showed selective effect on S2Me-H4R3 and S2Me-H3R8 with no effect against type I (PRMT1 and PRMT4) or other type II (PRMT7) enzymes. We also conducted cytotoxicity studies showing selective anti-tumor activity against LCLs. To further support the specificity of our inhibitors, we showed similar epigenetic changes and cytotoxic effects with shRNA and siRNA designed to knockdown PRMT5. Consistent with these findings, RNA-seq experiments using shRNA or CMP5 supported restored expression of multiple regulatory genes that compared similarly between shRNA and inhibitor-treated LCLs. This first-in-class drug was used here as a tool compound to explore the biological effect of PRMT5 inhibition and as a first step to promote the introduction of an entirely new therapeutic approach for patients with EBV+ lymphomas and other PRMT5-overexpressing B-cell lymphomas. It should also be highlighted that CMP5 and later generation PRMT5 inhibitors require further optimization for in vivo use.
In previous work, we described the post-transcriptional nature of PRMT5 expression via miR regulation and linked dysregulated expression of PRMT5 to aberrant expression of miR-96 in MCL 15 . Here we show that PRMT5 enhances its own expression by participating in a PRMT5/p65/HDAC3 complex that represses miR-96 transcription. Furthermore, while HDAC3 and PRMT5 confer transcriptional repressive activity to p65 at the miR-96 promoter, treatment of lymphoma cells with PRMT5 inhibitors leads to rapid dissociation of this repressive complex and differential association of p65 with p300 with enhanced recruitment to and subsequent transactivation of the miR-96 promoter. This data supports the notion of a dual role of p65 as repressor and activator that is dependent on PRMT5 activity.
Our findings link PRMT5 dysregulation and aberrant miR96 expression to LMP1 signaling through NF-kB, identifying cross-talk between viral oncogene activity and host regulatory networks to affect oncogenic pathways driven by PRMT5. It has been previously shown that EBV enhances survival of infected B cells through LMP1 by upregulating the expression of anti-apoptotic genes such as BFL1 42 and BCL2. 43 Here we demonstrate that PRMT5 overexpression is vital to the support of B cell immortalization, transformation and maintenance of the malignant phenotype.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Earlier studies indicated that LMP2A functions by altering normal BCR signaling through antigen-independent activation of downstream protein kinases. [44] [45] [46] [47] While PRMT5 inhibition does not have any direct effect on the expression of EBV-encoded proteins (Supplemental Figure 9 ), it does affect the expression of multiple cellular regulatory genes, highlighting its relevance as an epigenetic modifier capable of driving host and not viral oncogenic processes.
PTPROt is a tyrosine phosphatase that specifically targets BCR-triggered tyrosine kinases. 48 Here we showed by ChIP, direct PRMT5 recruitment to the PTPROt promoter. Additionally, PRMT5 inhibition led to PTPROt transcriptional de-repression and restoration of protein expression which, in turn, led to dephosphorylation of BCR signaling kinases. PTPROt expression decreases lymphoma cell proliferation and induces apoptosis. 36 We have also recently established the in vivo function of PTPROt through the generation of a transgenic mouse with B cell specific expression of PTPROt, and showed that PTPROt-mediated regulation of p53/Foxm1 suppresses the leukemic phenotype in a chronic lymphocytic leukemia mouse model. 49 Our results suggest that PRMT5-mediated down regulation of PTPROt following EBV infection and ensuing dysregulated BCR signaling, play a role in supporting the B cell immortalization process induced by EBV.
It is becoming more evident that dysregulation of histone-modifying enzymes is associated with cancer etiology and pathogenesis. We have taken advantage of the oncogenic potential of EBV and used it to illustrate the global epigenetic repressive role played by PRMT5 during B cell transformation. We have linked a potent oncogenic virus (EBV) to the overexpression of an epigenetic modifier (PRMT5) and characterized the critical role that PRMT5 plays in promoting its own overexpression through a repressive complex (p65/PRMT5/HDAC3) that transcriptionally silences miR96. Because of selective PRMT5 expression in malignant cells, the central role of this enzyme in regulating its own expression and its activity in transcriptionally silencing multiple regulatory genes, PRMT5 appears to be an ideal therapeutic target for lymphoma. In addition to providing an innovative strategy for EBV+ lymphomas as well as other subtypes of B-cell NHLs, this approach could be used to identify potential novel targets for therapy and will promote exploration of new combination strategies as treatment options for these diseases. 
Conflict-of-interest disclosure
The authors declare no competing financial interests. 
